Dr. Pourhassan never ceases to amaze... on an off

Dr. Pourhassan never ceases to amaze... on an off day and holiday weekend yet, two PRs; an interview on a Saturday evening which should be quite comprehensive from a medical perspective with Dr. Been. Hope he delves deeper into the HIV 'cure' newsmaking development as well as how they made the connection with American Regent and how much more vials of Leronlimab they might help get produced for CytoDyn besides commercialization and distribution... of course updates on end of Covid-19 trials as well as status of peer review and upcoming publishing, BLA for HIV and breast cancer trial... among many other things going on like how Leron and CytoDyn's trials stack up to competitors.

Sure looks like CytoDyn is going all out in getting help for manufacturing and commercializing Leron for Covid-19 (Distributor/Supplier American Regent) so I can't imagine they're doing it all without some indication(s) from the FDA to ramp up and guarantee manufacturing/production... I recall Dr. Pourhassan saying something to the effect, FDA requires and will have to get assurance of production capability.

The following may be of interest:

Informative well produced video about American Regent :

https://www.americanregent.com/video/

Also came across this list of 'competitors' and trials for Covid-19 therapies (as of end of May - maybe a few more by now):

https://www.businesswire.com/news/home/202005...nies-Drugs

Following from the FDA on therapeutic trials as of 5/11 (also may be more by now):

Quote:

---

Snapshot for Developing Therapeutics
Given the urgent nature of the pandemic and the number of companies and researchers developing COVID-19 related therapies, the following numbers may change frequently. As of May 11, 2020, the snapshot is:

144 active trials of therapeutic agents
Another 457 development programs for therapeutic agents in the planning stages

---

https://www.fda.gov/drugs/coronavirus-covid-1...ogram-ctap